121 related articles for article (PubMed ID: 28604107)
1. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Moreno L; Caron H; Geoerger B; Eggert A; Schleiermacher G; Brock P; Valteau-Couanet D; Chesler L; Schulte JH; De Preter K; Molenaar J; Schramm A; Eilers M; Van Maerken T; Johnsen JI; Garrett M; George SL; Tweddle DA; Kogner P; Berthold F; Koster J; Barone G; Tucker ER; Marshall L; Herold R; Sterba J; Norga K; Vassal G; Pearson AD
Expert Opin Drug Discov; 2017 Aug; 12(8):801-811. PubMed ID: 28604107
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma and its Target Therapies: A Medicinal Chemistry Review.
Gerges A; Canning U
ChemMedChem; 2024 May; 19(9):e202300535. PubMed ID: 38340043
[TBL] [Abstract][Full Text] [Related]
3. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer - An ACCELERATE Multistakeholder Consensus.
de Rojas T; Chiodin D; Pearson ADJ; Heenen D; Adamson P; Caron H; Vassal G
Clin Pharmacol Ther; 2024 Jan; 115(1):36-41. PubMed ID: 37885401
[TBL] [Abstract][Full Text] [Related]
4. Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
Bagatell R; DuBois SG; Naranjo A; Belle J; Goldsmith KC; Park JR; Irwin MS;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30572. PubMed ID: 37458162
[TBL] [Abstract][Full Text] [Related]
5. Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents.
Moreno L; DuBois SG; Glade Bender J; Mauguen A; Bird N; Buenger V; Casanova M; Doz F; Fox E; Gore L; Hawkins DS; Izraeli S; Jones DTW; Kearns PR; Molenaar JJ; Nysom K; Pfister S; Reaman G; Smith M; Weigel B; Vassal G; Zwaan CM; Paoletti X; Iasonos A; Pearson ADJ
J Clin Oncol; 2023 Jun; 41(18):3408-3422. PubMed ID: 37015036
[TBL] [Abstract][Full Text] [Related]
6. Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development.
Pearson ADJ; de Rojas T; Karres D; Reaman G; Scobie N; Fox E; Lesa G; Ligas F; Norga K; Nysom K; Pappo A; Weigel B; Weiner SL; Vassal G
J Natl Cancer Inst; 2024 Feb; 116(2):200-207. PubMed ID: 37975877
[TBL] [Abstract][Full Text] [Related]
7. Clinical research with targeted drugs in paediatric oncology.
Valle-Simón P; Borobia AM; Pérez-Martínez A
Drug Discov Today; 2023 Aug; 28(8):103672. PubMed ID: 37330039
[TBL] [Abstract][Full Text] [Related]
8. Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials.
DuBois SG; Bagatell R
J Clin Oncol; 2021 Aug; 39(23):2525-2527. PubMed ID: 34152837
[No Abstract] [Full Text] [Related]
9. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.
Ahmed AA; Zhang L; Reddivalla N; Hetherington M
Pediatr Hematol Oncol; 2017 Apr; 34(3):165-185. PubMed ID: 28662353
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma is composed of two super-enhancer-associated differentiation states.
van Groningen T; Koster J; Valentijn LJ; Zwijnenburg DA; Akogul N; Hasselt NE; Broekmans M; Haneveld F; Nowakowska NE; Bras J; van Noesel CJM; Jongejan A; van Kampen AH; Koster L; Baas F; van Dijk-Kerkhoven L; Huizer-Smit M; Lecca MC; Chan A; Lakeman A; Molenaar P; Volckmann R; Westerhout EM; Hamdi M; van Sluis PG; Ebus ME; Molenaar JJ; Tytgat GA; Westerman BA; van Nes J; Versteeg R
Nat Genet; 2017 Aug; 49(8):1261-1266. PubMed ID: 28650485
[TBL] [Abstract][Full Text] [Related]
11. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.
Amoroso L; Haupt R; Garaventa A; Ponzoni M
Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153
[TBL] [Abstract][Full Text] [Related]
12. Emerging and investigational therapies for neuroblastoma.
Applebaum MA; Desai AV; Glade Bender JL; Cohn SL
Expert Opin Orphan Drugs; 2017; 5(4):355-368. PubMed ID: 29062613
[TBL] [Abstract][Full Text] [Related]
13. From class waivers to precision medicine in paediatric oncology.
Pearson ADJ; Pfister SM; Baruchel A; Bourquin JP; Casanova M; Chesler L; Doz F; Eggert A; Geoerger B; Jones DTW; Kearns PR; Molenaar JJ; Morland B; Schleiermacher G; Schulte JH; Vormoor J; Marshall LV; Zwaan CM; Vassal G;
Lancet Oncol; 2017 Jul; 18(7):e394-e404. PubMed ID: 28677575
[TBL] [Abstract][Full Text] [Related]
14. 11q deletion in neuroblastoma: a review of biological and clinical implications.
Mlakar V; Jurkovic Mlakar S; Lopez G; Maris JM; Ansari M; Gumy-Pause F
Mol Cancer; 2017 Jun; 16(1):114. PubMed ID: 28662712
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma: Tumours get super-enhanced.
Bradley CA
Nat Rev Cancer; 2017 Jul; 17(8):455. PubMed ID: 28740110
[No Abstract] [Full Text] [Related]
16. Genetic susceptibility to neuroblastoma: current knowledge and future directions.
Ritenour LE; Randall MP; Bosse KR; Diskin SJ
Cell Tissue Res; 2018 May; 372(2):287-307. PubMed ID: 29589100
[TBL] [Abstract][Full Text] [Related]
17. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.
Russo R; Cimmino F; Pezone L; Manna F; Avitabile M; Langella C; Koster J; Casale F; Raia M; Viola G; Fischer M; Iolascon A; Capasso M
Carcinogenesis; 2017 Oct; 38(10):1011-1020. PubMed ID: 28968651
[TBL] [Abstract][Full Text] [Related]
18. Neural crest and cancer: Divergent travelers on similar paths.
Gallik KL; Treffy RW; Nacke LM; Ahsan K; Rocha M; Green-Saxena A; Saxena A
Mech Dev; 2017 Dec; 148():89-99. PubMed ID: 28888421
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
